Skip to main content

Tennis Elbow

3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Causeway Therapeutics
2 programs
1
1
TenoMiRPhase 21 trial
TenoMiRPhase 11 trial
Active Trials
NCT04670289Completed24Est. Aug 2021
NCT06192927Completed123Est. Jun 2025
CTM Biomedical
CTM BiomedicalON - Toronto
1 program
1
CTMPhase 21 trial
Active Trials
NCT06171555Unknown54Est. Dec 2025
Providence Therapeutics
1 program
Initial rehabilitation protocolN/A1 trial
Active Trials
NCT03987256Unknown58Est. Jul 2022
Ipsen
IpsenChina - Tianjin
1 program
Botulinum Toxin A InjectionPHASE_31 trial
Active Trials
NCT00437762Completed61Est. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenBotulinum Toxin A Injection
Causeway TherapeuticsTenoMiR
CTM BiomedicalCTM
Causeway TherapeuticsTenoMiR
Providence TherapeuticsInitial rehabilitation protocol

Clinical Trials (5)

Total enrollment: 320 patients across 5 trials

NCT00437762IpsenBotulinum Toxin A Injection

Effectiveness of Botulinum Toxin Injection in the Tennis Elbow Treatment

Start: Apr 2007Est. completion: Jun 201261 patients
Phase 3Completed
NCT06192927Causeway TherapeuticsTenoMiR

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

Start: Apr 2024Est. completion: Jun 2025123 patients
Phase 2Completed
NCT06171555CTM BiomedicalCTM

Efficacy of CTM for Tennis ELbow

Start: Jan 2023Est. completion: Dec 202554 patients
Phase 2Unknown
NCT04670289Causeway TherapeuticsTenoMiR

Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

Start: Aug 2020Est. completion: Aug 202124 patients
Phase 1Completed
NCT03987256Providence TherapeuticsInitial rehabilitation protocol

ECRB Tendinopathy: Needling ± PRP After Failure of Rehabilitation

Start: Jan 2020Est. completion: Jul 202258 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.